The contrast media injectors are used to inject medical contrast medium (or contrast agents) to enhance the contrast of structures or fluids within the body in medical imaging (visibility of blood vessels and the gastrointestinal tract). Contrast media are used to enhance the quality of medical imaging such as CT, MRI, PET/CT and ultrasound. Their value has long been recognized by their regular use in the radiology department worldwide. Contrast media injectors (CMI) refer to the equipment used to inject contrast media into the body that enhances the visualization of the specific organs and tissues, thereby improving the overall quality of medical imaging procedures. The recent advances with contrast media injector technology are cutting costs by reducing contrast waste and automated data collection for the treatment dose.
The global contrast media injectors market report provides market size estimates (Revenue US$ million – 2014 to 2021) for key market segments based on product type (CT, MRI, and vascular injectors), its applications (cardiology, neurology, oncology, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).
The global contrast media injectors market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global contrast media injectors market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global contrast media injectors market and included in this report are Bracco Imaging S.p.A., Medrad, Inc. ulrich GmbH & Co. KG, VIVID IMAGING, Nemoto Kyorindo Co., Ltd. and Mallinckrodt Pharmaceuticals.